Accoutumance aux chimiothérapies et aux biothérapies
作者： J. Waton , C. Poreaux , A. Barbaud
DOI: 10.1016/J.REVAL.2014.11.004
关键词:
摘要: Resume L’incidence des reactions d’hypersensibilite aux chimiotherapies et biotherapies progresse, en raison de leur essor l’exposition repetee patients a ces traitements. Dans les hypersensibilites autres medicaments, une solution alternative est proposee mais sont rarement substituables l’arret du traitement peut mettre jeu le pronostic vital patient ; l’accoutumance alors la seule therapeutique.
elsevier.com
sci-hub.se 参考文章(12)
David I. Hong, Anahita F. Dioun, Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children. The Journal of Allergy and Clinical Immunology: In Practice. ,vol. 2, pp. 13- 19 ,(2014) , 10.1016/J.JAIP.2013.11.007
J. Boulanger, J.N. Boursiquot, G. Cournoyer, J. Lemieux, M.S. Masse, K. Almanric, M.P. Guay, The Comité de l’évolution Des pratiques en oncologie, Management of hypersensitivity to platinum- and taxane-based chemotherapy: cepo review and clinical recommendations Current Oncology. ,vol. 21, pp. 630- 641 ,(2014) , 10.3747/CO.21.1966
David I Hong, Lora Bankova, Katherine N Cahill, Timothy Kyin, Mariana C Castells, Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies. Expert Review of Clinical Immunology. ,vol. 8, pp. 43- 54 ,(2012) , 10.1586/ECI.11.75
Joana Caiado, Lennart Venemalm, Maria Conceição Pereira-Santos, Luis Costa, Manuel Pereira Barbosa, Mariana Castells, Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. The Journal of Allergy and Clinical Immunology: In Practice. ,vol. 1, pp. 494- 500 ,(2013) , 10.1016/J.JAIP.2013.06.002
Giuseppe Ribizzi, Donatella Bignardi, Daniele Farinini, Davide Sassos, Riccarda Gentile, Daniela Arecco, Domenica Rizzi, Susanna Voltolini, Carlo Serrati, Desensitization to natalizumab: clinical and immunological observations. Multiple Sclerosis Journal. ,vol. 19, pp. 376- 377 ,(2013) , 10.1177/1352458512448269
Annick Barbaud, Florence Granel, Julie Waton, Claire Poreaux, How to manage hypersensitivity reactions to biological agents European Journal of Dermatology. ,vol. 21, pp. 667- 674 ,(2011) , 10.1684/EJD.2011.1468
T Lobera, G Gastaminza, M Corominas, Hypersensitivity reactions to biological drugs. Journal of Investigational Allergology and Clinical Immunology. ,vol. 24, pp. 212- 225 ,(2014)
Larisa J Geskin, Sara K Story, Andrej A Petrov, Successful desensitization to brentuximab vedotin after hypersensitivity reaction. Journal of Drugs in Dermatology. ,vol. 13, pp. 749- ,(2014)
C. Poreaux, J.-P. Bronowicki, M. Debouverie, J.-L. Schmutz, J. Waton, A. Barbaud, Managing generalized interferon-induced eruptions and the effectiveness of desensitization Clinical & Experimental Allergy. ,vol. 44, pp. 756- 764 ,(2014) , 10.1111/CEA.12217
David H. Dreyfus, Christopher C. Randolph, Characterization of an anaphylactoid reaction to omalizumab. Annals of Allergy Asthma & Immunology. ,vol. 96, pp. 624- 627 ,(2006) , 10.1016/S1081-1206(10)63560-0